Table 2 Antimicrobial therapy administered during hospitalization in 3463 patients
From: Prospective Observational Study on acute Appendicitis Worldwide (POSAW)
| Patients receiving antibiotics | N = 3463 (%) |
|---|---|
| Metronidazole or ornidazole | 2021 (58.2%) |
| Third-generation cephalosporins | 1280 (37.0%) |
| Second-generation cephalosporins | 598 (17.2%) |
| Penicillins + beta lactams-inhibitors | 500 (14.4%) |
| First-generation cephalosporins | 437 (12.6%) |
| Second-generation quinolones | 304 (8.8%) |
| Aminoglycosides | 289 (8.3%) |
| Ureidopenicillins + beta lactams-inhibitors | 130 (3.7%) |
| Aminopenicillins | 61 (1.8%) |
| Carbapenems | 58 (1.7%) |
| Third-generation cephalosporins + beta lactams-inhibitors | 52 (1.5%) |
| Third-generation quinolones | 18 (0.5%) |
| Fourth-generation cephalosporins | 12 (0.3%) |
| Others | 15 (0.4%) |
